Codexis (CDXS) Competitors

$2.64 +0.04 (+1.54%)

As of 05/27/2026 04:00 PM Eastern

CDXS vs. OPK, GERN, IRWD, RIGL, and XOMA

Should you buy Codexis stock or one of its competitors? MarketBeat compares Codexis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Codexis include OPKO Health (OPK), Geron (GERN), Ironwood Pharmaceuticals (IRWD), Rigel Pharmaceuticals (RIGL), and XOMA Royalty (XOMA). These companies are all part of the "biotechnology" industry.

How does Codexis compare to OPKO Health?

Codexis (NASDAQ:CDXS) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, OPKO Health had 1 more articles in the media than Codexis. MarketBeat recorded 1 mentions for OPKO Health and 0 mentions for Codexis. Codexis' average media sentiment score of 0.00 beat OPKO Health's score of -0.50 indicating that Codexis is being referred to more favorably in the media.

Company	Overall Sentiment
Codexis	Neutral
OPKO Health	Negative

Codexis has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Codexis has higher earnings, but lower revenue than OPKO Health. Codexis is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.41	-$43.97M	-$0.37	N/A
OPKO Health	$606.90M	1.62	-$225.68M	-$0.27	N/A

OPKO Health has a net margin of -36.63% compared to Codexis' net margin of -40.97%. OPKO Health's return on equity of -16.78% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
OPKO Health	-36.63%	-16.78%	-10.98%

Codexis presently has a consensus target price of $5.00, indicating a potential upside of 89.39%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 19.23%. Given Codexis' higher possible upside, research analysts clearly believe Codexis is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

78.5% of Codexis shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

OPKO Health beats Codexis on 10 of the 17 factors compared between the two stocks.

How does Codexis compare to Geron?

Geron (NASDAQ:GERN) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

In the previous week, Geron had 4 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Geron and 0 mentions for Codexis. Geron's average media sentiment score of 0.91 beat Codexis' score of 0.00 indicating that Geron is being referred to more favorably in the media.

Company	Overall Sentiment
Geron	Positive
Codexis	Neutral

Geron has a net margin of -35.48% compared to Codexis' net margin of -40.97%. Geron's return on equity of -23.31% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Codexis	-40.97%	-68.09%	-23.72%

Codexis has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.40	-$83.50M	-$0.11	N/A
Codexis	$70.39M	3.41	-$43.97M	-$0.37	N/A

Geron presently has a consensus price target of $2.50, suggesting a potential upside of 98.41%. Codexis has a consensus price target of $5.00, suggesting a potential upside of 89.39%. Given Geron's higher possible upside, research analysts clearly believe Geron is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Geron has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

73.7% of Geron shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Geron beats Codexis on 10 of the 15 factors compared between the two stocks.

How does Codexis compare to Ironwood Pharmaceuticals?

Codexis (NASDAQ:CDXS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Codexis presently has a consensus target price of $5.00, suggesting a potential upside of 89.39%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 68.01%. Given Codexis' higher probable upside, equities analysts plainly believe Codexis is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Ironwood Pharmaceuticals had 3 more articles in the media than Codexis. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 0 mentions for Codexis. Ironwood Pharmaceuticals' average media sentiment score of 0.95 beat Codexis' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Ironwood Pharmaceuticals	Positive

78.5% of Codexis shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ironwood Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.41	-$43.97M	-$0.37	N/A
Ironwood Pharmaceuticals	$296.15M	2.04	$24.02M	$0.60	6.18

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Codexis' net margin of -40.97%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Codexis has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats Codexis on 13 of the 17 factors compared between the two stocks.

How does Codexis compare to Rigel Pharmaceuticals?

Codexis (NASDAQ:CDXS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Codexis' net margin of -40.97%. Rigel Pharmaceuticals' return on equity of 47.99% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Codexis presently has a consensus target price of $5.00, suggesting a potential upside of 89.39%. Rigel Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 84.87%. Given Codexis' higher possible upside, equities research analysts plainly believe Codexis is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 5 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 0 mentions for Codexis. Rigel Pharmaceuticals' average media sentiment score of 0.16 beat Codexis' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Rigel Pharmaceuticals	Neutral

Rigel Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.41	-$43.97M	-$0.37	N/A
Rigel Pharmaceuticals	$294.28M	1.85	$367.02M	$18.72	1.57

78.5% of Codexis shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 3.5% of Codexis shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Rigel Pharmaceuticals beats Codexis on 12 of the 16 factors compared between the two stocks.

How does Codexis compare to XOMA Royalty?

XOMA Royalty (NASDAQ:XOMA) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, XOMA Royalty had 2 more articles in the media than Codexis. MarketBeat recorded 2 mentions for XOMA Royalty and 0 mentions for Codexis. XOMA Royalty's average media sentiment score of 0.22 beat Codexis' score of 0.00 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Overall Sentiment
XOMA Royalty	Neutral
Codexis	Neutral

XOMA Royalty has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

XOMA Royalty presently has a consensus target price of $53.75, suggesting a potential upside of 28.77%. Codexis has a consensus target price of $5.00, suggesting a potential upside of 89.39%. Given Codexis' higher possible upside, analysts clearly believe Codexis is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XOMA Royalty has a net margin of 53.46% compared to Codexis' net margin of -40.97%. XOMA Royalty's return on equity of 12.56% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Codexis	-40.97%	-68.09%	-23.72%

XOMA Royalty has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$7.65M	68.40	$31.71M	$1.57	26.59
Codexis	$70.39M	3.41	-$43.97M	-$0.37	N/A

Summary

XOMA Royalty beats Codexis on 12 of the 15 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$236.33M	$3.38B	$6.40B	$12.48B
Dividend Yield	N/A	2.27%	2.75%	5.25%
P/E Ratio	-7.13	18.82	21.34	25.93
Price / Sales	3.41	348.24	583.50	103.17
Price / Cash	N/A	122.89	43.13	56.80
Price / Book	5.50	7.16	10.48	7.14
Net Income	-$43.97M	$24.25M	$3.56B	$337.13M
7 Day Performance	4.35%	2.56%	1.82%	2.16%
1 Month Performance	-6.38%	4.71%	3.19%	4.34%
1 Year Performance	13.30%	65.58%	36.76%	37.22%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	2.7222 of 5 stars	$2.64 +1.5%	$5.00 +89.4%	+3.5%	$236.33M	$70.39M	N/A	250
OPK OPKO Health	2.4777 of 5 stars	$1.27 +3.3%	$1.55 +22.0%	-0.8%	$928.76M	$606.90M	N/A	1,373
GERN Geron	2.9527 of 5 stars	$1.26 flat	$2.50 +98.4%	-15.4%	$808.32M	$183.88M	N/A	70	Analyst Upgrade
IRWD Ironwood Pharmaceuticals	2.7149 of 5 stars	$3.85 -1.8%	$6.23 +61.9%	+495.9%	$639.19M	$296.15M	6.42	220
RIGL Rigel Pharmaceuticals	3.066 of 5 stars	$29.19 +1.3%	$54.50 +86.7%	+50.3%	$533.23M	$294.28M	1.56	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. OPK, GERN, IRWD, RIGL, and XOMA

How does Codexis compare to OPKO Health?

Summary

How does Codexis compare to Geron?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Summary

How does Codexis compare to Rigel Pharmaceuticals?

Summary

How does Codexis compare to XOMA Royalty?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. OPK, GERN, IRWD, RIGL, and XOMA

How does Codexis compare to OPKO Health?

Does the media favor CDXS or OPK?

Which has more volatility and risk, CDXS or OPK?

Which has higher earnings and valuation, CDXS or OPK?

Is CDXS or OPK more profitable?

Do analysts prefer CDXS or OPK?

Do institutionals & insiders have more ownership in CDXS or OPK?

Summary

How does Codexis compare to Geron?

Does the media favor GERN or CDXS?

Is GERN or CDXS more profitable?

Which has preferable earnings and valuation, GERN or CDXS?

Do analysts prefer GERN or CDXS?

Which has more volatility and risk, GERN or CDXS?

Do institutionals & insiders hold more shares of GERN or CDXS?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Do analysts rate CDXS or IRWD?

Does the media favor CDXS or IRWD?

Do insiders and institutionals hold more shares of CDXS or IRWD?

Which has better earnings & valuation, CDXS or IRWD?

Is CDXS or IRWD more profitable?

Which has more risk and volatility, CDXS or IRWD?

Summary

How does Codexis compare to Rigel Pharmaceuticals?

Is CDXS or RIGL more profitable?

Do analysts recommend CDXS or RIGL?

Which has more volatility & risk, CDXS or RIGL?

Does the media refer more to CDXS or RIGL?

Which has preferable earnings & valuation, CDXS or RIGL?

Do institutionals & insiders hold more shares of CDXS or RIGL?

Summary

How does Codexis compare to XOMA Royalty?

Do institutionals and insiders hold more shares of XOMA or CDXS?

Does the media favor XOMA or CDXS?

Which has more volatility and risk, XOMA or CDXS?

Do analysts recommend XOMA or CDXS?

Is XOMA or CDXS more profitable?

Which has higher earnings & valuation, XOMA or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools